Endo International PLC was incorporated in Ireland on October 31, 2013. It is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products as well as medical devices. The Compnay's business segments are U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals and International Pharmaceuticals. The U.S. Branded Pharmaceuticals segment includes a variety of branded prescription products related to treating and managing pain as well as its urology and men's health, endocrinology and orthopedic products. The marketed products that are included in this segment include Lidoderm, OPANA ER, Voltaren Gel, Percocet, BELBUCA, Fortesta Gel, Testim, Aveed, Supprelin LA, and XIAFLEX. The U.S. Generic Pharmaceuticals segment consists of a differentiated product portfolio including high barrier to entry products, first to file or first to market opportunities, that are difficult to formulate, difficult to manufacture or face complex legal and regulatory challenges. The product offerings of this segment include products in the pain management, urology, CNS disorders, immunosuppression, oncology, women's health and cardiovascular disease markets. The International Pharmaceuticals segment includes a variety of specialty pharmaceutical products for the Canadian, Mexican, South African and world markets. Paladin, based in Canada, has a portfolio of products serving growing therapeutic areas, including ADHD, pain, women's health and oncology. Somar, based in Mexico, develops, manufactures and markets high-quality generic, branded generic and over-the-counter products across key market segments including dermatology and anti-infectives. Litha, based in South Africa, is a diversified healthcare group providing services, products and solutions to public and private hospitals, pharmacies, general and specialist practitioners, as well as government healthcare programs. The Company's competitors include Abbott Laboratories, Allergan plc, Purdue Pharma, L.P., Jazz Pharmaceuticals plc, Shire plc, Horizon Pharma plc, and Mallinckrodt plc, Teva Pharmaceutical Industries, Mylan, Inc., and Impax Laboratories, Inc. The Company has 352 U.S. issued patents, 190 U.S. patent applications pending, 856 foreign issued patents, and 510 foreign patent applications pending. It also has licenses for 81 U.S. issued patents, 56 U.S. patent applications pending, 334 foreign issued patents and 139 foreign patent applications pending. In the United States, the development, testing, manufacture, holding, packaging, labeling, distribution, marketing, and sales of its products and the ongoing product development activities are subject to and rigorous government regulation.
Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content.